At a glance
ClinicalIndex Comparison RecordN/ACompleted· 15 enrolled
Drug / intervention
Bevacizumab +1 moredrug
Likely dose
Bevacizumab 10 mg/kgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Radiosurgery and Avastin for Recurrent Malignant Gliomas
In Brief
A clinical study evaluating Stereotactic Radiosurgery (SRS) and Bevacizumab for Malignant Glioma. Completed, enrolled 15 participants across 1 site.
Detailed Summary
The purpose of this study is to assess the central nervous system (CNS) toxicity in patients with recurrent malignant gliomas treated with concurrent Avastin and stereotactic radiosurgery (SRS).
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalignant Glioma
CountriesUnited States
CollaboratorsGenentech, Inc.
Timeline
N/ACompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedNov 2009
Enrollment StartDec 2009
Primary CompletionMar 2011
Study CompletionFeb 2012
TodayJul 2026
First PostedNov 20, 2009
Enrollment StartDec 1, 2009
Primary CompletionMar 1, 2011
Study CompletionFeb 1, 2012
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 16.6 years ago
Interventions
Stereotactic Radiosurgery (SRS)radiation
Tumor Volume \< 2.0cm receives 24 Gy in 1 fraction Tumor Volume 2.0-2.9cm receives 18 Gy in 1 faction Tumor Volume 3.0-4.9cm receives 25 Gy in 5Gy/fraction
Bevacizumabdrug
Bevacizumab (Avastin) 10 mg/kg given the day before SRS and 2 weeks after SRS